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Comparison of Safety and Efficacy of CYPHER® Stent and ENDEAVOR®
Stent in Patients with Acute ST Elevation Myocardial Infarction(STEMI)
undergoing emergency PCI and Analysis of Current Status of Emergency PCI
Green Channel in China
Lefeng Wang, Dapeng Zhang, Xinchun Yang, Yonggui Ge, Hongshi Wang, Weiming
Li, Li Xu, Yu Liu
Background: To compare the Safety and Efficacy of CYPHER® Sirolimus Stent and
ENDEAVOR® Zotarolimus Stent in Patients with Acute STEMI undergoing
emergency PCI, and to analysis Current Status of Emergency PCI Green Channel for
Patiens with STEMI in China.
Methods: 1020 patients were to be randomized, these patients were STEMI within 12
hours preparing emergency PCI, with “De novo”lesions in native coronary arteries,
and informed consent were written. and 145 cases were exclused(14.2%), totally 875
patients entered the study, 449 patients in ENDEAVOR group and 426 patients in
CYPHER group, totally 761 patients (86.9%) with 6-months Clinical follow-up. The
primary endpoints were cardiac mortality, myocardial infarction, and target lesion
revascularization (TLR) at 6 months.
Results: The Baseline Clinical Characteristics and Lesion Characteristics between 2
groups were no significant, Myocardial Infarction at 6 months between 2 groups were
2and 3(P =0.61),Stent Thrombosis at 6 months between 2 groups were both 2 cases(P
=0.96),Stent restenosis at 6 months between 2 groups were 5 and 1(P=0.09),Target
Lesion Revascularization at 6 months at 6 months between 2 groups were 6 and 3(P
=0.35),Cardiac death at 6 months were 12 and 9(P =0.56),Composite MACE at 6
months at 6 months were 20(4.5%)and 15(3.5%),P =0.48. The analysing of Emergency
Green Channel showed that the mean time of door to ballon was 119.2±80.1 minutes
(40~710 min), and only 47.6% patients whose D T B time was less than 90 minutes.
Conclusion: 1. There was no signal differential profile between Cypher and Endeavor
during 6 months in safety and efficacy. The antirestenotic efficacy of Endeavor was
somewhat inferior to the Cypher stent in Patients with STEMI undergoing emergency
PCI at 6-month follow-up. 2.Currently, AMI patients of Chinese first class hospital are
treated delayed seriously. There is still a big gap with PCI Guide which require 90min
from door to balloon.
Long-term Clinical Results from the All-comers LEADERS Trial: 4 Year
Follow-up Data.
Thomas A. Ischinger, Patrick W. Serruys, Marie-Claude Morice, Pawel Buszman,
Axel Linke, Volker Klauss, Diethmar Antoni, Hae Young Sohn, Roberto Corti, Franz
Eberli, William Wijns, Carlo Di Mario, Peter Juni, Stephan Windecker
Background: There is concern of an increased incidence of very late stent thrombosis,
associated with early generation DES potentially related to the durable polymer. The
Biolimus A9™ eluting stent platform (BES) releases biolimus from an abluminal
biodegradable polymer, polylactic acid (PLA), which is fully absorbed after 6-9
months. The LEADERS trial aimed to compare the safety and efficacy of BES with an
established stent platform releasing sirolimus from a durable polymer (SES) in a large
scale, all-comers, non-inferiority trial. The purpose of this presentation is to present the
4- year follow-up data to determine whether there are differences between the
biodegradable BES platform as compared to the durable polymer SES platform.
Methods: LEADERS is a multi-center, randomized, assessor-blind, non-inferiority
trial performed at 10 European sites in an all-comers, “real world” patient population
without limitation with respect to lesion length, number of treated lesions or vessels as
well as clinical indication (chronic stable angina vs. acute coronary syndromes). A total
of 1,707 patients were enrolled and randomly allocated 1:1 to BES or SES. The primary
endpoint was MACE (a composite of cardiac death, MI, or clinically-indicated TVR)
at 9 months. Secondary endpoints include death, cardiac death, MI, ST (ARC defined),
TLR and TVR. All patients are followed up to 5 years.
Results: BES sustained its non-inferiority to SES in terms of the primary endpoint of
MACE up to 4 year follow-up with a trend towards improved outcomes at 4 years
(18.7% for BES vs. 22.6% for SES, RR (95% CI): 0.81 (0.66 to 1.00), p
non-inf<0.0001,psup=0.051). Very late definite stent thrombosis (0.4% for BES vs.
1.8% for SES, RR(95% CI): 0.20 (0.06 to 0.67), psup=0.004) as well as very late
definite/ probable stent thrombosis (0.7% for BES vs. 2.4% for SES, RR (95% CI):
0.29 (0.12 to 0.73), psup=0.005) were less frequent with BES than SES at 4 years. The
4 year outcomes are summarized in table 1.
Conclusion: Our results suggest that BES represents a safe and effective alternative to
SES with robust clinical results up to 4-year follow-up.
Two-year results from a Randomized Comparison of Everolimus-Eluting and
Sirolimus-Eluting Stents in Patients Treated with Percutaneous Coronary
Intervention (SORT OUT IV Trial)
Lisette Okkels Jensen, Per Thayssen, Henrik S. Hansen, Evald H. Christiansen,
Michael Maeng, Hans-Henrik Tilsted, Anders Junker, Jan Ravkilde, Anne Kaltoft,
Morten Madsen, Henrik T. Soerensen, Leif Thuesen, Jens F. Lassen
Background: The sirolimus-eluting stent has demonstrated the least amount of late
lumen loss among previously released drug-eluting stents, but its long-term safety and
efficacy have not been compared head-to-head with the next-generation everolimus-
eluting stent
Methods: The Scandinavian Organization for Randomized Trials with Clinical
Outcome (SORT OUT) IV was a randomized multicenter, open-label, all-comer, two-
arm, non-inferiority trial comparing the everolimus-eluting stent with the
sirolimus-eluting stent in patients with coronary artery disease. The primary end point
was a composite of safety (cardiac death, myocardial infarction, definite stent
thrombosis) and efficacy (target vessel revascularization) parameters. Intention-to-treat
analyses were done at 9-month (primary end point) and two-year follow-up.
Results: 1,390 patients were assigned to receive the everolimus-eluting stent, and 1,384
patients were assigned to receive the sirolimus-eluting stent. At 9-month follow-up,
68 [4.9%] patients treated with the everolimus-eluting stent versus 72 [5.2%] patients
treated with the sirolimus-eluting stent experienced the primary end point (hazard ratio
(HR) = 0.94; 95% confidence interval (CI): 0.67 to 1.31) (p for non-inferiority = 0.01).
Two-year results will be available at the presentation.
Conclusion: Two-year results will be available at the presentation. 
Clinical Evaluation of the IN.PACT Drug-eluting Balloon for Treatment of
Femoro-popliteal Arterial Disease: Twelve Month Results from a Multicenter
Italian Registry
Antonio Micari, Angelo Cioppa, Giuseppe Vadalà, Fausto Castriota, Alberto
Cremonesi, Armando Liso, Alfredo Marchese, Chiara Grattoni, Paolo Pantaleo,
Paolo Rubino, Giancarlo Biamino
Background: This study evaluated the use of a drug-eluting balloon (DEB) for
treatment of femoropoliteal arterial disease.Conventional balloon angioplasty and
stenting in this setting is associated with a high restenosis rates within
12 months post-procedure. Recent data suggest that use of DEBs may reduce
restenosis. Twelve month outcomes following DEB use with provisional stenting are
described.
Methods: This prospective registry enrolled patients (Rutherford class 2, 3, or 4) with
reference vessel diameter of 3 to
7 mm and lesion/occlusion length ≤15 cm. Endpoints included primary patency rate,
target lesion revascularization (TLR), and changes in Rutherford class and ankle-
brachial index (ABI). Walking capacity, absolute claudication distance (ACD), and
quality of life (QOL) were also assessed
Results: At 12 months follow-up, 92/105 patients (87.6%) were evaluable. Baseline
ABI was 0.56 ± 0.15. Baseline Rutherford classification was 26.7% for class 2 and
64.8% for class 3. Most lesions were located in the superficial femoral artery (77.1%).
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